Summary
The main therapeutic indication for glucagon is the treatment of hypoglycaemia in insulin overdosed Type 1 (insulin-dependent) diabetic patients. We have previously shown that an intranasal spray of 7.5 mg glucagon with deoxycholic acid as surfactant was able to correct an i.v. insulin-induced hypoglycaemia in diabetic patients. However, bioavailability and stability needed to be improved before intranasal glucagon could be introduced into clinical practice. This has now been achieved with a freeze-dried mixture of glucagon (1 mg) and glycocholic acid (1 mg) as a surfactant. Kinetics and efficacy have been controlled by (1) comparing subcutaneous and intranasal glucagon in 12 healthy non-hypoglycaemic subjects; (2) testing intranasal glucagon in six Type 1 diabetic patients in whom hypoglycaemia was induced by an i.v. bolus of insulin and (3) comparing subcutaneous and intranasal glucagon in six Type 1 diabetic patients in whom hypoglycaemia was induced by adding extra subcutaneous regular insulin to their usual morning dosage. Our results show that 1 mg of intranasal glucagon is as effective as 1 mg of subcutaneous glucagon in terms of the rise in blood glucose. Differences in kinetics between the subcutaneous and the intranasal routes may be observed: intranasal glucagon initiates the blood glucose rise earlier than does the subcutaneous form but the effect of the latter is more sustained. Glycocholic acid appears to be a perfectly tolerated agent in acute conditions. The use of intranasal lyophylized glucagon, for the reversal of hypoglycaemia in Type 1 diabetes, seems to be a clinically relevant alternative to its parenteral equivalent and should now be ready to be introduced in the market.
Article PDF
Similar content being viewed by others
References
Goldgewicht C, Slama G, Papoz L, Tchobroutsky G (1983) Hypoglycaemic reactions in 172 Type 1 (insulin-dependent) diabetic patients. Diabetologia 24: 95–99
Muhlhauser I, Berger M, Sonnenberg G, Koch J, Jörgens V, Schernthaner G, Scholz V (1985) Incidence and management of severe hypoglycemia in 434 adults with insulin-dependent diabetes mellitus. Diabetes Care 8: 268–273
Freychet L, Rizkalla SW, Desplanque N, Basdevant A, Zirinis P, Tchobroutsky G, Slama G (1988) Effect of glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. Lancet I: 1364–1366
Pontiroli AE, Alberetto M, Pozza G (1983) Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J 287: 462–463
Pontiroli AE, Alberetto M, Pozza G (1985) Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection. Acta Diab Lat 22: 103–109
Arnold JD, Swift GF (1988) Intranasal glucagon for hypoglycaemia. Lancet II: 216
Slama G, Freychet L, Desplanque N (1988) Intranasal glucagon for hypoglycaemia. Lancet II: 799
Elrick H, Witten TA, Yoshiaki A (1958) Glucagon treatment of insulin reactions. N Engl J Med 258: 476–480
Alberetto M, Pontiroli AE, Calderara A, Pajetta E, Pozza G (1988) Intranasal glucagon for hypoglycaemic crises in patients with Type 1 (insulin-dependent) diabetes. Diabetologia 31: 463 A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Slama, G., Alamowitch, C., Desplanque, N. et al. A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon. Diabetologia 33, 671–674 (1990). https://doi.org/10.1007/BF00400568
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00400568